Results 211 to 220 of about 458,270 (348)

Protecting Public Health from Outside the Physician's Office: A Century of FDA Regulation from Drug Safety Labeling to Off-Label Drug Promotion

, 2007
Katherine Helm
openalex   +1 more source

Heterogeneity of Rheumatoid Arthritis–Associated Interstitial Lung Disease by Longitudinal Forced Vital Capacity Trajectory and Associations With Disease Outcomes

Arthritis Care &Research, EarlyView.
Objective We aimed to identify unique disease trajectories within rheumatoid arthritis–associated interstitial lung disease (RA‐ILD) based on longitudinal forced vital capacity (FVC) values and their associated clinical outcomes. Methods We performed a cohort study of RA‐ILD within the Veterans Health Administration from 1999 to 2021.
Bryant R. England, Yangyuna Yang, Punyasha Roul, Tate M. Johnson, Scott M. Matson, Grant W. Cannon, Brian C. Sauer, Jeffrey R. Curtis, Joshua F. Baker, Ted R. Mikuls   +9 more
wiley   +1 more source

Exploring Patients’ Profiles Associated With the Resolution of Acute Calcium Pyrophosphate Arthritis Treated With Colchicine and Prednisone: Post Hoc Analysis of a Randomized Controlled Trial

Arthritis Care &Research, EarlyView.
Objective The objective was to identify factors determining acute arthritis resolution and safety with colchicine and prednisone in acute calcium pyrophosphate (CPP) crystal arthritis. Methods We conducted a post hoc analysis of the COLCHICORT trial, which compared colchicine and prednisone for the treatment of acute CPP crystal arthritis, using a ...
Tristan Pascart, Laurène Norberciak, Pascal Richette, Pierre Robinet, Aurore Pacaud, Gauthier Marchasson, Thibault Rabin, Hélène Luraschi, Pierre Maciejasz, Anne‐France Georgel, Augustin Latourte, Hang‐Korng Ea, Sébastien Ottaviani, Charlotte Jauffret, Vincent Ducoulombier   +14 more
wiley   +1 more source

“Off-Label” Indications for Oncology Drug Use and Drug Compendia: History and Current Status

, 2005

openalex   +2 more sources

Effectiveness and Safety of Baricitinib for Juvenile Idiopathic Arthritis–Associated Uveitis or Chronic Anterior Antinuclear Antibody–Positive Uveitis

Arthritis Care &Research, EarlyView.
Objective To evaluate the efficacy and safety of baricitinib in pediatric patients with active juvenile idiopathic arthritis–associated uveitis (JIA‐U) or chronic anterior antinuclear antibody–positive uveitis, who had an inadequate response to methotrexate (MTX) or biologic disease‐modifying antirheumatic drugs (bDMARDs).
Athimalaipet V. Ramanan, Catherine M. Guly, Gabriele Simonini, Stuart Y. Keller, Priyanka Sen, Thorsten Holzkaemper, Joana Araújo, Pierre Quartier   +7 more
wiley   +1 more source

Tre-DST: A Drug Susceptibility Test for <i>Mycobacterium tuberculosis</i> Using Solvatochromic Trehalose Probes. [PDF]

ACS Infect Dis
Schwartz LA, Brodeth AL, Susilo CT, Rodolf AA, Ivanov T, Mendoza Corrales E, Kumar SS, Kamariza M.   +7 more
europepmc   +1 more source

Additional file 4: of Study of serious adverse drug reactions using FDA-approved drug labeling and MedDRA

, 2019
Leihong Wu, Taylor Ingle, Zhichao Liu, Anna Zhao-Wong, Stephen Harris, Shraddha Thakkar, Guangxu Zhou, Junshuang Yang, Joshua Xu, Darshan Mehta, Weigong Ge, Weida Tong, Hong Fang   +12 more
openalex   +1 more source

Temporal Trends in and Associations With Nonsteroidal Anti‐inflammatory Drug Prescription in Adult and Pediatric Patients With Inflammatory Bowel Disease

Arthritis Care &Research, EarlyView.
Objective Recent inflammatory bowel disease (IBD) treatment guidelines have recommended against nonsteroidal anti‐inflammatory drug (NSAID) use despite prevalent musculoskeletal symptoms and opioid overuse in this population. Given the discordance between changing national guidelines and potential clinical utility, we sought to assess national temporal
Adam S. Mayer, Rui Xiao, Andrew Grossman, Meenakshi Bewtra, Michael D. George, Pamela F. Weiss   +5 more
wiley   +1 more source

Mapping cellular targets of covalent cancer drugs in the entire mammalian body. [PDF]

Cell
Pang Z, Leung VH, Wang CC, Attarpour A, Rinaldi A, Shen H, Moya-Garzon MD, Sigua LH, Rammel C, Selke A, Glynn C, Yender M, Xu S, Moslehi JJ, Wu P, Long JZ, Goubran M, Cravatt BF, Ye L.   +18 more
europepmc   +1 more source

Sarilumab in Polyarticular‐Course Juvenile Idiopathic Arthritis: Dose‐Finding and One‐Year Analysis of a Phase 2b, Open‐Label, Multicenter Study

Arthritis Care &Research, Accepted Article.
Objective This study assessed sarilumab in treating patients with polyarticular‐course juvenile idiopathic arthritis (pcJIA). Methods This phase 2b, open‐label study (NCT02776735) consisted of three sequential parts (each with a core‐treatment and extension‐phase). During part 1, three doses were assessed in two weight groups (Group A/B: ≥30–60 kg/≥10–<
Fabrizio De Benedetti, Inmaculada C. Penadés, Irina Nikishina, Ivan Foeldvari, Alberto J. Spindler, Anna Kozlova, Nadina Rubio‐Pérez, Pierre Quartier, Zbigniew Żuber, Raul Barria, Daniel Clemente, Gabriel V. Cornejo, Katherine Marzan, Nancy Liu, Christine Xu, Stephen DiMartino, Angeliki Giannelou, Fei Cao‐Ghoul, Bolanle Akinlade, Lydie Baret‐Cormel   +19 more
wiley   +1 more source